Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
MALVERN, Pa., May 01, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its first quarter financial results before the market opens on May 9, 2017.
Management will conduct a conference call at 4:30 PM ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 5101760 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
